Giellepi & CK Nutraceuticals extend distribution deal for Microsmin Plus

Microsmin Plus is a flavonoids complex standardized in diosmin that is supported by published clinical trials in the area of healthy leg veins.  According to Giellepi, Microsmin Plus delivers nine times increased bioavailability versus standard Diosmin. 

For example, a 2021 paper published in Nutrients​​ detailed results of an eight week randomized, double-blind, placebo-controlled trial using a daily Microsmin Plus dose of 450 mg. Results of the study, which included 72 people showed significant improvements in markers of leg vein health at four and eight weeks.

“The results of this study showed that the administration of low-dose Microsmin Plus was safe and effective in relieving symptoms and improving QoL in subjects with CVD [Chronic Venous Disease],” wrote scientists, led by researchers at Italy’s University Magna Graecia of Catanzaro.

“A timely solution”​

Commenting on the extended agreement, Michael Chernyak, CK Nutraceuticals president, said: “Despite a long history of use in the area of vascular health, standard diosmin suffers from poor bioavailability and highly variable absorption when consumed orally.  Microsmin Plus overcomes these issues – it’s a very timely solution for what we believe is an underserved opportunity space.”

Giellepi also recently introduce Microsmin Plus SG to expand the ingredients to applications like soft gels and gummy formats.

Fabio Terruzzi, Director at Giellepi, said:: “We look forward to continued partnership with CK Nutraceuticals within the North American market.  CK has a strong track record in the U.S. and Canada, both which are of strategic importance to Giellepi.  Also, we are conducting additional clinical studies, to further substantiate the expanding range of valuable therapeutic benefits from Microsmin Plus.”